Revotek announced that it has received clearance from the National Health Commission of China to begin a clinical study in the West China Hospital, Chengdu, with its first stem cell 3D bioprinting product, REVOVAS.
New inhalers would have near-zero Global Warming Potential propellant
Therapeutic use of the product is for short term symptomatic relief of colds, chills and influenza including chesty coughs
The sale is expected to close in the first quarter of 2022
Heterologous booster vaccination refers to the use of vaccine boosters from different technology platforms from the prime vaccines, which could improve the overall immune response and enhance protection against other variants
It is India’s 1st indigenously developed Receptor Binding Domain Protein sub-unit vaccine against Covid-19
The transaction generates upfront cash proceeds of $442 million for Syncona's holding in Gyroscope
Victor Dillard as VP Corporate Development and Lorna Peers as VP Finance
Fitch estimates JPL's EBITDA to drop significantly in FY23 due to lower volume and narrowing of the margin to 11% (FY22 estimate: 14%).
Launching Dexamethasone, Azacitidine, Carboprost, and Atropine for the Institutional Market
Subscribe To Our Newsletter & Stay Updated
